GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entia Biosciences Inc (OTCPK:ERGO) » Definitions » Net Income

Entia Biosciences (Entia Biosciences) Net Income : $-1.40 Mil (TTM As of Dec. 2016)


View and export this data going back to 2007. Start your Free Trial

What is Entia Biosciences Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Entia Biosciences's Net Income for the three months ended in Dec. 2016 was $-0.43 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2016 was $-1.40 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Entia Biosciences's Earnings per Share (Diluted) for the three months ended in Dec. 2016 was $-0.02.


Entia Biosciences Net Income Historical Data

The historical data trend for Entia Biosciences's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entia Biosciences Net Income Chart

Entia Biosciences Annual Data
Trend Jul07 Jul08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.26 -3.11 -2.30 -2.26 -1.40

Entia Biosciences Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.27 -0.40 -0.29 -0.43

Entia Biosciences Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Entia Biosciences's Net Income for the fiscal year that ended in Dec. 2016 is calculated as

Net Income(A: Dec. 2016 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.396+0+0+0
=-1.40

Entia Biosciences's Net Income for the quarter that ended in Dec. 2016 is calculated as

Net Income(Q: Dec. 2016 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.433+0+0+0
=-0.43

Net Income for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entia Biosciences  (OTCPK:ERGO) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Entia Biosciences's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2016 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Entia Biosciences Net Income Related Terms

Thank you for viewing the detailed overview of Entia Biosciences's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Entia Biosciences (Entia Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.
Executives
Carl J Johnson director, officer: President and CEO
Hausman Marvin S Md director, officer: Chairman, CSTO 825 THIRD AVE, 40TH FL, NEW YORK NY 10022
Anka Capital Ltd 10 percent owner ROOM 2204 22F WEST TOWER SHUN TAK CENTRE, 200 CONNAUGHT ROAD CENTRAL, SHEUNG WAN K3 -
Cheuk Ho Tam 10 percent owner ROOM 2204 22F WEST TOWER SHUN TAK CENTER, 200 CONNAUGHT ROAD CENTRAL, SHEUNG WAN K3 -
Wah On Wong 10 percent owner ROOM 2204 22F WEST TOWER SHUN TAK CENTER, 200 CONNAUGHT ROAD CENTRAL, SHEUNG WAN K3 -

Entia Biosciences (Entia Biosciences) Headlines